PhI of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma

Cancer
Lauren C Pinter-Brown
An Open-Label, Multi-Center, Non Randomized Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma
Lymphoid Leukemia

Study Description

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Eligibility

You can participate in this study if you

  • must be 18 years of age or older

You cannot participate in this study if you

  • are pregnant or breast-feeding
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.